BRPI0620755A2 - adenovìrus adipogênicos como um biomarcardor para doenças - Google Patents
adenovìrus adipogênicos como um biomarcardor para doenças Download PDFInfo
- Publication number
- BRPI0620755A2 BRPI0620755A2 BRPI0620755-3A BRPI0620755A BRPI0620755A2 BR PI0620755 A2 BRPI0620755 A2 BR PI0620755A2 BR PI0620755 A BRPI0620755 A BR PI0620755A BR PI0620755 A2 BRPI0620755 A2 BR PI0620755A2
- Authority
- BR
- Brazil
- Prior art keywords
- adenovirus
- adipogenic
- cancer
- subject
- sample
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 119
- 230000002293 adipogenic effect Effects 0.000 title claims abstract description 97
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 25
- 201000010099 disease Diseases 0.000 title claims abstract description 24
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 116
- 201000011510 cancer Diseases 0.000 claims abstract description 82
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 35
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 35
- 238000012360 testing method Methods 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims description 74
- 239000000523 sample Substances 0.000 claims description 51
- 210000001519 tissue Anatomy 0.000 claims description 51
- 241000700605 Viruses Species 0.000 claims description 44
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 40
- 206010060862 Prostate cancer Diseases 0.000 claims description 36
- 229960005486 vaccine Drugs 0.000 claims description 34
- 238000003556 assay Methods 0.000 claims description 31
- 150000007523 nucleic acids Chemical group 0.000 claims description 29
- 230000004064 dysfunction Effects 0.000 claims description 25
- 210000000481 breast Anatomy 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 230000001965 increasing effect Effects 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 101710132601 Capsid protein Proteins 0.000 claims description 13
- 101710094648 Coat protein Proteins 0.000 claims description 13
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 13
- 101710125418 Major capsid protein Proteins 0.000 claims description 13
- 101710141454 Nucleoprotein Proteins 0.000 claims description 13
- 101710083689 Probable capsid protein Proteins 0.000 claims description 13
- 210000002307 prostate Anatomy 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 12
- 230000001919 adrenal effect Effects 0.000 claims description 11
- 230000003263 anti-adenoviral effect Effects 0.000 claims description 11
- 239000012472 biological sample Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 210000000133 brain stem Anatomy 0.000 claims description 7
- 210000000653 nervous system Anatomy 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- -1 stool Substances 0.000 claims description 7
- 238000002965 ELISA Methods 0.000 claims description 6
- 241001135569 Human adenovirus 5 Species 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 241000509400 Human adenovirus D37 Species 0.000 claims description 5
- 208000016222 Pancreatic disease Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 238000006386 neutralization reaction Methods 0.000 claims description 5
- 206010058314 Dysplasia Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 101710199711 Early E1A protein Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 241000321096 Adenoides Species 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 210000002534 adenoid Anatomy 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 239000000344 soap Substances 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 abstract description 62
- 235000020824 obesity Nutrition 0.000 abstract description 59
- 208000015181 infectious disease Diseases 0.000 abstract description 23
- 239000003550 marker Substances 0.000 abstract description 8
- 238000004393 prognosis Methods 0.000 abstract description 8
- 239000000090 biomarker Substances 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 55
- 210000004027 cell Anatomy 0.000 description 54
- 102000004190 Enzymes Human genes 0.000 description 21
- 108090000790 Enzymes Proteins 0.000 description 21
- 102000039446 nucleic acids Human genes 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 20
- 241000282693 Cercopithecidae Species 0.000 description 19
- 210000000577 adipose tissue Anatomy 0.000 description 19
- 235000014113 dietary fatty acids Nutrition 0.000 description 19
- 229930195729 fatty acid Natural products 0.000 description 19
- 239000000194 fatty acid Substances 0.000 description 19
- 238000003752 polymerase chain reaction Methods 0.000 description 18
- 150000004665 fatty acids Chemical class 0.000 description 17
- 108091005899 fibrous proteins Proteins 0.000 description 14
- 208000010370 Adenoviridae Infections Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 102000034240 fibrous proteins Human genes 0.000 description 13
- 230000003520 lipogenic effect Effects 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 241000282412 Homo Species 0.000 description 12
- 230000003321 amplification Effects 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 206010060931 Adenovirus infection Diseases 0.000 description 10
- 241000288961 Saguinus imperator Species 0.000 description 10
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 10
- 229940021704 adenovirus vaccine Drugs 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 9
- 210000001789 adipocyte Anatomy 0.000 description 9
- 238000007857 nested PCR Methods 0.000 description 9
- 239000002853 nucleic acid probe Substances 0.000 description 9
- 150000003626 triacylglycerols Chemical class 0.000 description 9
- 241000287828 Gallus gallus Species 0.000 description 8
- 235000013330 chicken meat Nutrition 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- 206010022489 Insulin Resistance Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 5
- 230000007882 cirrhosis Effects 0.000 description 5
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 206010014561 Emphysema Diseases 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 241000598171 Human adenovirus sp. Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 4
- 231100000590 oncogenic Toxicity 0.000 description 4
- 230000002246 oncogenic effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 208000003200 Adenoma Diseases 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 3
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 230000005980 lung dysfunction Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 239000008207 working material Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100037403 Carbohydrate-responsive element-binding protein Human genes 0.000 description 2
- 101710101477 Carbohydrate-responsive element-binding protein Proteins 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 206010069150 Discordant twin Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000006372 lipid accumulation Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000002105 tongue Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 208000020576 Adrenal disease Diseases 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 108010048401 CCAAT-Enhancer-Binding Proteins Proteins 0.000 description 1
- 102000009122 CCAAT-Enhancer-Binding Proteins Human genes 0.000 description 1
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical group COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 description 1
- 101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 1
- 101710108984 Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010063075 Cryptogenic cirrhosis Diseases 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000033640 Hereditary breast cancer Diseases 0.000 description 1
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000701123 Human adenovirus 31 Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100026375 Protein PML Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 244000292604 Salvia columbariae Species 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 208000013222 Toxemia Diseases 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000002556 adrenal cortex cell Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 210000000040 apocrine gland Anatomy 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 241000701792 avian adenovirus Species 0.000 description 1
- 210000001084 basket cell Anatomy 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 208000003816 familial cirrhosis Diseases 0.000 description 1
- 108091022862 fatty acid binding Proteins 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 208000015707 frontal fibrosing alopecia Diseases 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000004730 hepatocarcinogenesis Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010120 metabolic dysregulation Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000005994 pancreas dysfunction Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011472 radical prostatectomy Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004092 self-diagnosis Methods 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- ACOJCCLIDPZYJC-UHFFFAOYSA-M thiazole orange Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1=CC=C2C(C=C3N(C4=CC=CC=C4S3)C)=CC=[N+](C)C2=C1 ACOJCCLIDPZYJC-UHFFFAOYSA-M 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/075—Adenoviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75340205P | 2005-12-27 | 2005-12-27 | |
| US60/753,402 | 2005-12-27 | ||
| PCT/US2006/062632 WO2007120362A2 (en) | 2005-12-27 | 2006-12-27 | Adipogenic adenoviruses as a biomarker for disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0620755A2 true BRPI0620755A2 (pt) | 2011-11-22 |
Family
ID=38610014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0620755-3A BRPI0620755A2 (pt) | 2005-12-27 | 2006-12-27 | adenovìrus adipogênicos como um biomarcardor para doenças |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US7442511B2 (enExample) |
| EP (2) | EP2390372A1 (enExample) |
| JP (1) | JP2009521707A (enExample) |
| KR (1) | KR20080114683A (enExample) |
| CN (1) | CN101389768B (enExample) |
| AU (1) | AU2006342053A1 (enExample) |
| BR (1) | BRPI0620755A2 (enExample) |
| CA (1) | CA2635269A1 (enExample) |
| MX (1) | MX2008008453A (enExample) |
| RU (1) | RU2008130893A (enExample) |
| WO (1) | WO2007120362A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507418B2 (en) * | 2005-09-09 | 2009-03-24 | Obetech, Llc | Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes |
| KR20080114683A (ko) * | 2005-12-27 | 2008-12-31 | 오베테크, 엘엘씨 | 질병에 대한 바이오마커로서의 지방생성 아데노바이러스 |
| US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| JP2009156254A (ja) * | 2007-12-05 | 2009-07-16 | Ibiden Co Ltd | 排気ガス処理体の保持シール部材及び排気ガス処理装置 |
| PT2268618E (pt) | 2008-03-03 | 2015-10-12 | Novartis Ag | Compostos e composições moduladores da actividade tlr |
| WO2010011440A2 (en) * | 2008-06-16 | 2010-01-28 | Obetech Llc | Diagnosis and treatment of lipogenic adenovirus infection associated with adipose tissue hypertrophy |
| AU2010258677B2 (en) | 2009-06-10 | 2016-10-06 | Glaxosmithkline Biologicals S.A. | Benzonaphthyridine-containing vaccines |
| TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為ｔｌｒ活性調節劑之化合物及組合物 |
| JP5988492B2 (ja) | 2009-09-02 | 2016-09-07 | ノバルティス アーゲー | Ｔｌｒ活性モジュレーターを含む免疫原性組成物 |
| WO2011050299A2 (en) * | 2009-10-22 | 2011-04-28 | Obetech Llc | Adenovirus infection in animals |
| WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
| WO2011063131A1 (en) | 2009-11-18 | 2011-05-26 | Nohands, Llc | Method and system for preventing virus-related obesity and obesity related diseases |
| WO2011084549A1 (en) | 2009-12-15 | 2011-07-14 | Novartis Ag | Homogeneous suspension of immunopotentiating compounds and uses thereof |
| EA031379B1 (ru) | 2010-03-23 | 2018-12-28 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
| US20130052635A1 (en) * | 2010-03-25 | 2013-02-28 | Richard L. Atkinson | Method For Detecting Lipogenic Adenovirus |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| JP5965397B2 (ja) * | 2010-07-08 | 2016-08-03 | ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティー アンド アグリカルチュラル アンド メカニカル カレッジ | 非アルコール性脂肪肝疾患の予防および治療のためのアデノウイルスａｄ３６ｅ４ｏｒｆ１タンパク質 |
| US20130178517A1 (en) * | 2010-07-09 | 2013-07-11 | Richard L. Atkinson | Methods And Compositions For Treatment Of Lipogenic Virus Related Conditions |
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| ES2670863T3 (es) | 2013-02-01 | 2018-06-01 | Glaxosmithkline Biologicals Sa | Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll |
| US9925254B2 (en) | 2014-11-05 | 2018-03-27 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against Campylobacter jejuni |
| US11458151B2 (en) | 2018-02-12 | 2022-10-04 | Inimmune Corporation | Toll-like receptor ligands |
| US20230333111A1 (en) * | 2018-10-05 | 2023-10-19 | Minomic International Ltd. | Biomarker combinations for determining aggressive prostate cancer |
| JP2023547677A (ja) | 2020-11-04 | 2023-11-13 | エリゴ・バイオサイエンス | キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69435075T2 (de) * | 1993-03-17 | 2009-02-19 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten |
| WO1998044946A1 (en) * | 1997-04-04 | 1998-10-15 | Obetech, Llc | Viral obesity methods and compositions |
| JP2000072800A (ja) * | 1998-08-26 | 2000-03-07 | Toagosei Co Ltd | 抗アデノウイルス３７型モノクローナル抗体及びその用途 |
| CA2632013C (en) * | 2005-11-30 | 2013-02-26 | Wayne State University | Adenovirus 36 e4 orf 1 gene and protein and their uses |
| KR20080114683A (ko) * | 2005-12-27 | 2008-12-31 | 오베테크, 엘엘씨 | 질병에 대한 바이오마커로서의 지방생성 아데노바이러스 |
-
2006
- 2006-12-27 KR KR1020087018439A patent/KR20080114683A/ko not_active Ceased
- 2006-12-27 BR BRPI0620755-3A patent/BRPI0620755A2/pt not_active Application Discontinuation
- 2006-12-27 EP EP11176754A patent/EP2390372A1/en not_active Withdrawn
- 2006-12-27 JP JP2008548837A patent/JP2009521707A/ja active Pending
- 2006-12-27 RU RU2008130893/13A patent/RU2008130893A/ru not_active Application Discontinuation
- 2006-12-27 CN CN200680053371.XA patent/CN101389768B/zh not_active Expired - Fee Related
- 2006-12-27 MX MX2008008453A patent/MX2008008453A/es active IP Right Grant
- 2006-12-27 WO PCT/US2006/062632 patent/WO2007120362A2/en not_active Ceased
- 2006-12-27 US US11/616,799 patent/US7442511B2/en not_active Expired - Fee Related
- 2006-12-27 AU AU2006342053A patent/AU2006342053A1/en not_active Abandoned
- 2006-12-27 CA CA002635269A patent/CA2635269A1/en not_active Abandoned
- 2006-12-27 EP EP06851054.4A patent/EP1977009B1/en active Active
-
2008
- 2008-10-24 US US12/257,937 patent/US7745110B2/en not_active Expired - Fee Related
- 2008-10-24 US US12/257,967 patent/US7910310B2/en not_active Expired - Fee Related
-
2011
- 2011-02-07 US US13/022,219 patent/US20110189235A1/en not_active Abandoned
-
2013
- 2013-08-14 US US13/966,631 patent/US20130323273A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1977009A2 (en) | 2008-10-08 |
| US20090087833A1 (en) | 2009-04-02 |
| US20070218081A1 (en) | 2007-09-20 |
| US7910310B2 (en) | 2011-03-22 |
| CA2635269A1 (en) | 2007-10-25 |
| EP2390372A1 (en) | 2011-11-30 |
| US20130323273A1 (en) | 2013-12-05 |
| CN101389768B (zh) | 2015-11-25 |
| CN101389768A (zh) | 2009-03-18 |
| MX2008008453A (es) | 2008-11-28 |
| EP1977009B1 (en) | 2016-08-17 |
| US7442511B2 (en) | 2008-10-28 |
| KR20080114683A (ko) | 2008-12-31 |
| US7745110B2 (en) | 2010-06-29 |
| WO2007120362A2 (en) | 2007-10-25 |
| AU2006342053A1 (en) | 2007-10-25 |
| WO2007120362A3 (en) | 2008-08-14 |
| US20090087455A1 (en) | 2009-04-02 |
| RU2008130893A (ru) | 2010-02-10 |
| US20110189235A1 (en) | 2011-08-04 |
| EP1977009A4 (en) | 2009-06-03 |
| JP2009521707A (ja) | 2009-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7910310B2 (en) | Adipogenic adenoviruses as a biomarker for disease | |
| Kwon et al. | Serological prevalence, genetic identification, and characterization of the first strains of avian hepatitis E virus from chickens in Korea | |
| USRE42129E1 (en) | Viral obesity methods and compositions | |
| Hooi et al. | Coxsackievirus A16 in a 1-day-old mouse model of central nervous system infection shows lower neurovirulence than Enterovirus A71 | |
| US20090220946A1 (en) | Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes | |
| Wang et al. | Tissue tropism and target cells of bluetongue virus in the chicken embryo | |
| CN114807361B (zh) | 马兜铃酸毒性分子标志物及其应用 | |
| CN103757137A (zh) | 同步检测三种猪病毒的共有引物核酸扩增方法与试剂盒 | |
| WO2010011440A2 (en) | Diagnosis and treatment of lipogenic adenovirus infection associated with adipose tissue hypertrophy | |
| CN110628728A (zh) | 靶向癌症的重组溶瘤基因-腺病毒及其构建方法和应用 | |
| Murakami et al. | Pleomorphic malignant mesothelioma in a broiler breeder infected with avian leucosis virus subgroup J | |
| Maliye et al. | Evaluation of human papillomavirus as a risk factor in prostate cancer pathogenesis | |
| CN117431247B (zh) | 一种靶向igf-1r的核酸适配体及其应用 | |
| CN108754030A (zh) | 一种人ki多瘤病毒的荧光定量pcr引物和探针及其应用 | |
| CN120629571A (zh) | Lepr基因或蛋白作为靶标在制备胆管细胞癌治疗产品中的用途 | |
| Rockett | Characterising the pathogenesis and biology of newly described human polyomaviruses | |
| US20120244187A1 (en) | Adenovirus Infection In Animals | |
| Magrin et al. | Changing prevalence of hepatitis C virus (HCV) types/subtypes and hepatocellular carcinoma (HCG) | |
| Levrero et al. | Cancer formation in WAP-HBV-X transgenic animals a new model to study pX oncogenic potential in vivo | |
| Haydon et al. | Hepatitis C viral genotypes, modes of transmission, and incubation of infection in hepatocellular carcinoma (HCC) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |